Sichuan Biokin Stock Hits Day Low Amid Price Pressure, Closes at CNY 264.60

Sichuan Biokin Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 4.18% to reach an intraday low of CNY 264.60. This performance stands in contrast to the China Shanghai Composite, which fell by 1.26% during the same period. Over the past week, Sichuan Biokin has seen a more significant downturn, with a 7.8% decrease, while the broader index showed a slight gain of 0.41%. In terms of longer-term performance, the stock has faced challenges, with a year-to-date decline of 18.11%, compared to a 2.85% increase in the Shanghai Composite. Despite a positive annual return of 17.47%, the company has reported negative results for the last four consecutive quarters, including a significant drop in net sales and net profit. Sichuan Biokin operates within the Pharmaceuticals & Biotechnology sector and holds a market capitalization of CNY 29,530 million. The company's financial metrics indicate a challenging environment, with a return on equity of -11.97% and a price-to-book ratio of 4.12, reflecting its current market position.